Compounds > diosgenin glucoside
Page last updated: 2024-11-12

diosgenin glucoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diosgenin glucoside: RN given refers to (3beta,25R)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diosgenin 3-O-beta-D-glucoside : A sterol 3-beta-D-glucoside having diosgenin as the sterol component. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11827970
CHEMBL ID395414
CHEBI ID74020
SCHEMBL ID2734312
MeSH IDM0147760

Synonyms (48)

Synonym
trillin
AC-11225
14144-06-0
disogluside
CHEMBL395414
chebi:74020 ,
bdbm50021400
collettiside i
(25r)-3beta-(beta-d-glucopyranosyloxy)spirost-5-ene
disoglusidum
unii-8ki671f2ns
diosgenin glucoside
disogluside [inn]
disoglusido [inn-spanish]
disoglusido
8ki671f2ns ,
disoglusidum [inn-latin]
S9068
AKOS015960440
(25r)-spirost-5-en-3beta-ol 3-o-beta-d-glucopyranoside
(3beta,25r)-spirost-5-en-3-yl beta-d-glucopyranoside
diosgenin 3-o-beta-d-glucoside
(25r)-spirost-5-en-3beta-yl beta-d-glucopyranoside
3-o-(glcbeta)-(25r)-spirost-5en-3beta-ol
diosgenin 3-beta-d-glucoside
1h-pyrrole-2,4-dicarboxylicacid, 3,5-dimethyl-
SCHEMBL2734312
C20709
(3beta,25r)-spirost-5-en-3-ol 3-o-beta-d-glucopyranoside
diosgenin 3-o-beta-d-glucopyranoside
b-d-glucopyranoside, (3b,25r)-spirost-5-en-3-yl
AC-34930
Q-100152
diosgenin-glucoside
3-o-beta-d-glc-diosgenin
diosgeninglucoside
diosgenin 3-glucoside
collettinside i
prosapogenin d'3
melongoside b
funkioside a
Q27144338
(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(1s,2s,4s,5'r,6r,7s,8r,9s,12s,13r,16s)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxyoxane-3,4,5-triol
CCG-270115
CS-0009743
HY-N0730
A885676
MS-30378

Research Excerpts

Overview

Diosgenin glucoside (Dios) is a saponin compound extracted from Tritulus terrestris L.

ExcerptReferenceRelevance
"Diosgenin glucoside (Dios) is a saponin compound extracted from Tritulus terrestris L."( Diosgenin glucoside provides neuroprotection by regulating microglial M1 polarization.
Guo, H; Hu, L; Li, R; Wang, F; Wang, S; Yang, H, 2017)		2.62

Bioavailability

ExcerptReferenceRelevance
"Diosgenin was modified to control its in vivo bioavailability by conjugating a hydrophilic unit, tetraethylene glycol."( Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
Hong, BN; Hong, HN; Kang, TH; Kim, DH; Kim, TW; Le, HT; Lim, CW; Park, KH, 2012)		0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
sterol 3-beta-D-glucosideAny beta-D-glucoside derived from a sterol.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
hexacyclic triterpenoidA triterpenoid that consists of a hexacyclic ring system.
spiroketalA cyclic ketal in which the ketal carbon is the only common atom of two rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interleukin-2Homo sapiens (human)Kd0.00000.00001.30375.4700AID1156797
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
positive regulation of immunoglobulin productionInterleukin-2Homo sapiens (human)
positive regulation of plasma cell differentiationInterleukin-2Homo sapiens (human)
negative regulation of B cell apoptotic processInterleukin-2Homo sapiens (human)
positive regulation of B cell proliferationInterleukin-2Homo sapiens (human)
positive regulation of activated T cell proliferationInterleukin-2Homo sapiens (human)
negative regulation of protein phosphorylationInterleukin-2Homo sapiens (human)
adaptive immune responseInterleukin-2Homo sapiens (human)
leukocyte activation involved in immune responseInterleukin-2Homo sapiens (human)
transcription by RNA polymerase IIInterleukin-2Homo sapiens (human)
immune responseInterleukin-2Homo sapiens (human)
cell adhesionInterleukin-2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationInterleukin-2Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayInterleukin-2Homo sapiens (human)
cell-cell signalingInterleukin-2Homo sapiens (human)
positive regulation of cell population proliferationInterleukin-2Homo sapiens (human)
natural killer cell activationInterleukin-2Homo sapiens (human)
T cell differentiationInterleukin-2Homo sapiens (human)
positive regulation of cell growthInterleukin-2Homo sapiens (human)
positive regulation of type II interferon productionInterleukin-2Homo sapiens (human)
positive regulation of interleukin-17 productionInterleukin-2Homo sapiens (human)
positive regulation of tissue remodelingInterleukin-2Homo sapiens (human)
interleukin-2-mediated signaling pathwayInterleukin-2Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinInterleukin-2Homo sapiens (human)
negative regulation of apoptotic processInterleukin-2Homo sapiens (human)
response to ethanolInterleukin-2Homo sapiens (human)
positive regulation of regulatory T cell differentiationInterleukin-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterleukin-2Homo sapiens (human)
regulation of T cell homeostatic proliferationInterleukin-2Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesInterleukin-2Homo sapiens (human)
negative regulation of lymphocyte proliferationInterleukin-2Homo sapiens (human)
negative regulation of inflammatory responseInterleukin-2Homo sapiens (human)
positive regulation of inflammatory responseInterleukin-2Homo sapiens (human)
activated T cell proliferationInterleukin-2Homo sapiens (human)
positive regulation of dendritic spine developmentInterleukin-2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandInterleukin-2Homo sapiens (human)
response to tacrolimusInterleukin-2Homo sapiens (human)
negative regulation of T-helper 17 cell differentiationInterleukin-2Homo sapiens (human)
regulation of CD4-positive, alpha-beta T cell proliferationInterleukin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
cytokine activityInterleukin-2Homo sapiens (human)
interleukin-2 receptor bindingInterleukin-2Homo sapiens (human)
protein bindingInterleukin-2Homo sapiens (human)
growth factor activityInterleukin-2Homo sapiens (human)
kinase activator activityInterleukin-2Homo sapiens (human)
carbohydrate bindingInterleukin-2Homo sapiens (human)
kappa-type opioid receptor bindingInterleukin-2Homo sapiens (human)
glycosphingolipid bindingInterleukin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular spaceInterleukin-2Homo sapiens (human)
extracellular regionInterleukin-2Homo sapiens (human)
extracellular spaceInterleukin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID672435Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in body weight at 20 mg/kg, po administered QD measured 9 weeks after STZ challenge (Rvb = 34.15 +/- 1.16 g)2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID672436Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 10 mg/kg, po administered QD measured 1 week after STZ challenge (Rvb = 516.33 +/- 46.73 mg/dl)2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID294375Cytotoxicity against human erythrocytes assessed as hemolytic activity after 60 mins2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Exploration of the correlation between the structure, hemolytic activity, and cytotoxicity of steroid saponins.
AID672437Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 10 mg/kg, po administered QD measured 9 weeks after STZ challenge (Rvb = 529.90 +/- 49.17 mg/dl)2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID672443Protective activity against hearing loss in streptozotocin-induced diabetic ICR mouse using 8 KHz tone bursts at 20 mg/kg, po administered QD measured after 8 weeks by auditory brainstem response test2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID672439Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 20 mg/kg, po administered QD measured 9 weeks after STZ challenge (Rvb = 529.90 +/- 49.17 mg/dl)2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID672445Protective activity against hearing loss in streptozotocin-induced diabetic ICR mouse assessed as decrease in positive A peak latency at 20 mg/kg, po administered QD measured after 8 weeks by auditory middle latency response test2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID294370Cytotoxicity against human erythrocytes assessed as hemolytic activity at 100 ug/ml after 60 mins2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Exploration of the correlation between the structure, hemolytic activity, and cytotoxicity of steroid saponins.
AID1156799Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID672434Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in body weight at 20 mg/kg, po administered QD measured 1 week after STZ challenge (Rvb = 33.25 +/- 0.75 g)2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID672433Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in body weight at 10 mg/kg, po administered QD measured 9 weeks after STZ challenge (Rvb = 34.15 +/- 1.16 g)2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID672447Protective activity against hearing loss in streptozotocin-induced diabetic ICR mouse assessed as increase in negative A peak-positive A peak amplitude at 20 mg/kg, po administered QD measured after 8 weeks by auditory middle latency response test2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID672442Protective activity against hearing loss in streptozotocin-induced diabetic ICR mouse using 4 KHz tone bursts at 20 mg/kg, po administered QD measured after 8 weeks by auditory brainstem response test2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID672438Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 20 mg/kg, po administered QD measured 1 week after STZ challenge (Rvb = 516.33 +/- 46.73 mg/dl)2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
AID1156797Binding affinity to IL-2 (unknown origin)2014European journal of medicinal chemistry, Aug-18, Volume: 83Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID672432Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in body weight at 10 mg/kg, po administered QD measured 1 week after STZ challenge (Rvb = 33.25 +/- 0.75 g)2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Small molecular weight PEGylation of diosgenin in an in vivo animal study for diabetic auditory impairment treatment.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's4 (44.44)24.3611
2020's3 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.89 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
xanthenes
Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.		2.3110xanthene
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.3110glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		3.1850D-glucopyranoseepitope;
mouse metabolite
cholesteryl succinate
cholesteryl succinate: RN given refers to (3beta)-isomer. cholesteryl hemisuccinate : A dicarboxylic acid monoester resulting from the formal condensation of the hydroxy group of cholesterol with one of the carboxy groups of succinic acid. A detergent that is often used to replace cholesterol in protein crystallography, biochemical studies of proteins, and pharmacology.		2.3110cholestane ester;
dicarboxylic acid monoester;
hemisuccinate		detergent
diosgenin
[no description available]		3.33603beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal		antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite
daidzin
daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).		2.1107-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
dodecyl-beta-d-maltoside
dodecyl beta-D-maltoside : A glycoside resulting from attachment of a dodecyl group to the reducing-end anomeric centre of a beta-maltose molecule.		2.3110disaccharide derivative;
glycoside		detergent
dioscin
[no description available]		2.4620hexacyclic triterpenoid;
spiroketal;
spirostanyl glycoside;
trisaccharide derivative		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 1.14.18.1 (tyrosinase) inhibitor;
hepatoprotective agent;
metabolite
oleanolic acid 3-acetate
oleanolic acid 3-acetate: from Gardenia jasminoides; RN given for (3beta)-isomer		2.110
eglumetad
eglumetad: LY-354740 is the active isomer, LY-366563 is the inactive isomer, and LY 314582 is the racemate; structure given in first source		2.3110L-alpha-amino acid
ononin
[no description available]		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
monosaccharide derivative		plant metabolite
ganoderic acid a
[no description available]		2.110triterpenoid
ganoderiol f
ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source		2.110triterpenoid
glycosides
[no description available]		1.9710
formononetin
[no description available]		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite
luteolin
[no description available]		2.1103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
7,3'-dihydroxy-4'-methoxyisoflavone
7,3'-dihydroxy-4'-methoxyisoflavone: isolated from Astragali radix; structure in first source. calycosin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at the 3' position and a methoxy group at the 4' position.		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones		antioxidant;
metabolite
luteolin-7-glucoside
luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.110beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite
apigetrin
apigetrin: structure given in first source. apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.110beta-D-glucoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative		antibacterial agent;
metabolite;
non-steroidal anti-inflammatory drug
calycosin-7-o-beta-d-glucopyranoside
calycosin-7-O-beta-D-glucoside: from Radix Astragali. calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
spd-304
SPD-304: structure in first source		2.110
biphenyl-indanone a
biphenyl-indanone A: an mGluR2 agonist; structure in first source		2.3110biphenyls
ly 379268
LY 379268: group II metabotropic glutamate receptor agonist; structure in first source. LY 379268 : An organic heterobicyclic compound that is (1R,5S)-2-oxabicyclo[3.1.0]hexane carrying amino, carboxy, and carboxy groups at positions 4R, 4R and 6R, respectively. It is a potent agonist of group II metabotropic glutamate receptors mGluR2 and mGluR3 (EC50 = 2.69 nM and 4.48 nM, respectively) that exhibits antipsychotic-like action in animal models of schizophrenia.		2.3110amino dicarboxylic acid;
bridged compound;
organic heterobicyclic compound		antipsychotic agent;
anxiolytic drug;
metabotropic glutamate receptor agonist;
neuroprotective agent
ly 341495
LY 341495: structure in first source		2.3110
prosapogenin a
[no description available]		2.0310steroid saponin
astragaloside IV
[no description available]		2.110pentacyclic triterpenoid;
triterpenoid saponin		anti-inflammatory agent;
antioxidant;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
neuroprotective agent;
plant metabolite;
pro-angiogenic agent
sapogenins
Sapogenins: The aglucon moiety of a saponin molecule. It may be triterpenoid or steroid, usually spirostan, in nature.		1.9710
ganoderic acid f
ganoderic acid F: isolated from Ganoderma lucidum; structure in first source		2.110triterpenoid
glycolipids
[no description available]		2.3110
ganoderic acid c2
ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source		2.110triterpenoid
ConditionIndicatedRelationship StrengthStudiesTrials
Extravascular Hemolysis
[description not available]		02.0310
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.0310
Alloxan Diabetes
[description not available]		02.0710
Bone Cancer
[description not available]		02.610
Osteogenic Sarcoma
[description not available]		02.610
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.610
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		07.610
Cancer of Cervix
[description not available]		02.2510
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.2510
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.2510
Injuries, Spinal Cord
[description not available]		02.1710
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		02.1710